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Adaptation of tumor cells to the host is a major cause of cancer progression, failure of therapy, and ultimately 
death. Immune selection drives this adaptation in human cancer by enriching tumor cells with a cancer stem 
cell–like (CSC-like) phenotype that makes them resistant to CTL-mediated apoptosis; however, the mechanisms 
that mediate CSC maintenance and proliferation are largely unknown. Here, we report that CTL-mediated 
immune selection drives the evolution of tumor cells toward a CSC-like phenotype and that the CSC-like phe-
notype arises through the Akt signaling pathway via transcriptional induction of Tcl1a by Nanog. Furthermore, 
we found that hyperactivation of the Nanog/Tcl1a/Akt signaling axis was conserved across multiple types of 
human cancer. Inhibition of Nanog in a murine model of colon cancer rendered tumor cells susceptible to 
immune-mediated clearance and led to successful, long-term control of the disease. Our findings establish a 
firm link among immune selection, disease progression, and the development of a stem-like tumor phenotype 
in human cancer and implicate the Nanog/Tcl1a/Akt pathway as a central molecular target in this process.
Introduction
Despite heroic efforts by humankind to combat cancer over mil-
lennia, this disease remains the second leading cause of death 
in the United States, afflicting approximately 50% of all men 
and 30% of all women (1). It is now clear that a central reason 
that a cure for cancer has thus far been elusive is the constant 
adaptation of tumor cells to the defenses — internal and exter-
nal — mounted by the host they inhabit (2–4). For example, 
conventional interventions, such as radiation or chemotherapy, 
may eliminate the bulk of the tumor but spare highly aggressive 
cancer cells that have an exceptional capacity to survive, self-re-
new, and advance the malignancy (5–7). These residual cells 
have recently been found to possess key stem-like attributes and 
have thus been coined “cancer stem cells” (CSCs) (8–10). CSCs 
are believed to be primarily responsible for tumor progression, 
metastasis, and relapse after therapy (11–13). The existence and 
persistence of these cells may therefore explain the failure of cur-
rent cancer treatment modalities.
The dynamics of CSC maintenance and propagation remain 
largely unknown. Transformed cells are continuously subjected 
to immune selection; cells that can survive immune attack are 
preferentially retained, while those that cannot are eradicated (3). 
We have recently shown, in a mouse model of cervical carcinoma, 
that a vaccination regimen which induces CTL-mediated immune 
selection drives the evolution of tumor cells toward a stem-like 
and antiapoptotic phenotype in a process that requires the Nanog 
transcription factor (14). This finding argues that immune selec-
tion can be a perpetuating force for cancer progression. However, 
the molecular mechanism by which Nanog mediates immune 
escape and the relevance of Nanog expression in human cancer 
have not been previously explored. Both of these issues are essen-
tial for clinical translation and form the premise of this study.
Here, we demonstrate for the first time to our knowledge that 
immune selection of human cancer cells causes enrichment of 
a subset of cells with high Nanog expression. These cells exhibit 
stem-like, antiapoptotic properties and are impervious to immune 
attack. Importantly, the phenotype of these cells is critically depen-
dent on Nanog, which, through its transcriptional activity, triggers 
the T cell leukemia/lymphoma 1A/Akt (Tcl1a/Akt) signaling axis. 
We report that Nanog expression in tumor tissue is correlated 
with the stage of disease and prognosis of patients with cervical 
neoplasia. Furthermore, we found that Nanog overexpression — as 
well as the stem-like, antiapoptotic tumor phenotype this protein 
promotes — is conserved across multiple types of human cancer. 
Finally, we provide proof of the principle in a preclinical model 
that Nanog inhibition is an effective strategy to control human 
cancer, particularly in the context of immune-based therapy.
Results
Immune selection enhances the growth and stem-like properties of tumor 
cells. We applied in vitro immune selection to generate human 
tumor cells impervious to lysis by antigen-specific CTLs, as illus-
trated in Figure 1A. Human cervical cancer cells from the CaSki 
line (designated P0 cells) were retrovirally transduced with the 
mouse major histocompatibility complex (MHC) class I mole-
cule H2-Db, pulsed with the H2-Db–restricted E7 epitope from 
human papillomavirus type 16, and mixed with mouse E7-spe-
cific CTLs. The live tumor cells were recovered as the P1 line. 
Further rounds of selection were used to generate the P2 and P3 
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populations, which were sequentially more resistant to lysis by 
antigen-specific CTLs or granzyme B, as demonstrated by the 
frequency of active caspase-3+ cells (Figure 1, B and C). Notably, 
over 90% of P3 cells survived when mixed with CTLs, compared 
with only 10% of the P0 cells (Figure 1B). Relative to the P0 cells, 
the P3 cells also proliferated more quickly (Figure 1D) and had 
nearly 3-times more cyclin A and 10-times less p21 expression 
(Figure 1E).
In addition to displaying a faster growth rate, the P3 cells exhib-
ited a stem-like phenotype. These cells readily formed spheres 
when cultured under suspension conditions (Figure 1F) and were 
more tumorigenic than the parental P0 line when transplanted 
into NOD/SCID mice (Figure 1, G and H). Furthermore, the P3 
population was enriched in cells expressing a panel of stemness 
markers. For example, compared with P0 cells, there were about 
3-times more P3 cells expressing CD133, CD166, or EpCAM (Fig-
ure 1I). There were 7-times more P3 cells than P0 cells expressing 
CD44 (Figure 1I). Thus, these data indicate that immune selec-
tion increases the growth rate and stem-like phenotype of human 
tumor cells, consistent with what has been reported for other types 
of conventional cancer treatment, such as chemotherapy or radi-
ation therapy (5–7).
Immune selection enriches Nanog-expressing tumor cells. To exam-
ine the molecular basis for the enhanced growth rate and stem-
like phenotype of tumor cells following immune selection, we 
assessed the expression of a set of stemness markers from the 
P0, P1, P2, and P3 populations. Among these markers, we only 
found a substantial difference in Nanog expression among the 
various populations (Figure 2A). Specifically, Nanog accumu-
lated with sequential rounds of immune selection, and the total 
level of Nanog protein was 3-fold higher in P3 cells than in P0 
cells (Figure 2A). The overall increase in Nanog expression in the 
P3 line was likely due to enrichment of Nanog+ cells, as opposed 
to upregulation of Nanog, since the frequency of Nanog+ cells 
rose from around 5% in the P0 line to around 90% in the P3 line 
(18-fold enrichment) (Figure 2B). It is possible that the mere 
presence of CTLs in culture with tumor cells exerts metabolic 
stress that enriches Nanog+ cells. To exclude this possibility, we 
performed selection by mixing CaSki-H2-Db cells pulsed with 
either E7 or irrelevant (Ova) peptide together with E7-specific 
T cells. While CaSki-H2-Db cells loaded with E7 peptide are sub-
jected to both immune attack and metabolic stress, those loaded 
with Ova peptide are subjected only to metabolic stress. We mea-
sured Nanog levels in the tumor cells after sequential rounds 
of selection and found that Nanog expression increased after 
selection with E7 but not with Ova peptide (Supplemental Fig-
ure 1; supplemental material available online with this article; 
doi:10.1172/JCI64057DS1). Furthermore, we did not observe 
Nanog upregulation or development of an immune-resistant 
phenotype after mixing E7 peptide–pulsed CaSki-H2-Db cells 
with irrelevant Ova-specific CD8+ T cells for several cycles (data 
not shown). Therefore, we conclude that metabolic stress does 
not contribute to the development of a stem-like and immune-re-
sistant phenotype in tumor cells under immune selection. Thus, 
immune selection depletes cells lacking Nanog and spares those 
containing Nanog in an antigen-specific manner. This suggests 
that Nanog may confer a growth and survival advantage to tumor 
cells and may promote the formation of cells resembling CSCs.
Nanog is critical for the augmented growth and stem-like properties of 
immune-selected tumor cells. To test this possibility, we treated P3 
cells with siRNA-targeting Nanog (siNanog) or siRNA-targeting 
GFP (siGFP) control. We observed that administration of siNanog 
reduced by over 2-fold the frequency of CD133+ or CD44+ P3 
cells (Figure 2D). Furthermore, siNanog decreased cyclin A pro-
tein levels by 10 fold and increased p21 levels by 5.3 fold in the 
P3 line (Figure 2C). Consistent with these changes in protein lev-
els, siNanog-treated cells proliferated more slowly, formed over 
3-times fewer spheres, and contained nearly 4-times more apop-
totic cells when mixed with E7-specific CTLs compared with siG-
FP-treated cells (Figure 2, E–G). Taken together, our data indicate 
that Nanog provides a growth and survival advantage to tumor 
cells and contributes to their stem-like phenotype.
It is conceivable that Nanog expression in tumor cells influences 
the antigen-processing or -presentation pathway, which could 
account for decreased sensitivity to lysis by CTLs. Therefore, we 
assessed (a) MHC class I (H2-Db) expression in CaSki-H2-Db cells 
transduced with empty vector or Nanog and (b) the presentation 
of E7 peptide through MHC class I to E7-specific CD8+ T cells. 
We found that both MHC class I expression and presentation of 
E7 peptide to E7-specific CD8+ T cells were virtually identical, 
regardless of Nanog expression status in tumor cells (Supplemen-
tal Figure 2). Thus, we conclude that Nanog in tumor cells does 
not influence MHC class I expression or antigen presentation by 
tumor cells.
We next tested the possibility that Nanog expression in tumor 
cells may alter the functional capacity or survival of antigen-spe-
cific CTLs. We found there was no difference in CTL effector 
cytokine (IFN-γ) production, tumor surface expression of the 
apoptosis-inducing molecule Fas ligand, or survival of E7-spe-
cific CTLs mixed with E7-loaded tumor cells, regardless of Nanog 
expression (Supplemental Figures 2 and 3). Thus, we conclude 
that Nanog expression in tumor cells renders these cells imper-
vious to lysis by CTLs but does not affect the intrinsic functional 
capacity of the CTLs.
Nanog promotes an immune-resistant and stem-like phenotype in tumor 
cells through Akt-dependent upregulation of Mcl-1. We next sought to 
determine the mechanism by which Nanog confers a growth and 
survival advantage, as well as a stem-like phenotype, to tumor cells. 
Figure 1
Immune selection enhances the stem-like properties and tumorige-
nicity of human cancer cells. (A) Diagram depicting the process of in 
vitro immune selection of human cervical cancer cells. (B and C) Flow 
cytometry analysis of the frequency of apoptotic (active caspase-3+) 
cells in the P0, P1, P2, and P3 populations (B) after incubation with 
E7-specific CTLs at a 1:1 ratio for 4 hours (isotype control staining is 
indicated by solid gray regions; anti-active caspase-3 staining is indi-
cated by the black lines) or (C) after intracellular delivery of granzyme 
B. (D) Growth rate of P0 versus P3 cells in culture. Cells were har-
vested at the indicated times and counted after trypan blue staining to 
exclude dead cells. (E) Western blot analysis of expression of cyclin 
A and p21 in P0 versus P3 cells. β-Actin was included as an internal 
loading control. Numbers below blots indicate expression as measured 
by fold change. (F) Sphere-forming capacity of P0 versus P3 cells in 
low-density suspension culture. Original magnification, ×40. (G) Tum-
origenicity of P0 versus P3 cells inoculated at indicated doses into 5 
NOD/SCID mice per group. (H) Tumor burden 12 days after injection of 
103 P0 or P3 cells. (I) Flow cytometry analysis of stemness markers in 
P0, P1, P2, and P3 populations (isotype control staining is indicated by 
solid gray region; staining for stemness markers is indicated by black 
lines). Error bars represent mean ± SD.
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Figure 2
Nanog confers stem-like properties as 
well as a growth and survival advantage to 
immune-selected human cancer cells. (A) 
Western blot analysis of a panel of stem-
ness factors in P0, P1, P2, and P3 popu-
lations. β-Actin was included as an internal 
loading control. (B) Immunofluorescence 
analysis of the frequency of Nanog+ cells 
in P0, P1, P2, and P3 populations. β-Actin 
was included as an internal loading control. 
(C) Western blot analysis of Nanog, cyclin 
A, and p21 expression in P3 cells treated 
with siGFP or siNanog. β-Actin was used 
as an internal loading control. (D) Flow 
cytometry analysis of stemness marker 
(CD133 and CD44) expression in siGFP- 
or siNanog-treated P3 cells. (E) Growth 
rate of siGFP- versus siNanog-treated P3 
cells in culture. Cells were harvested at 
the indicated times and counted after try-
pan blue staining to exclude dead cells. (F) 
Sphere-forming capacity of siGFP- versus 
siNanog-treated P3 cells in low-density 
suspension culture. (G) Flow cytome-
try analysis of the frequency of apoptotic 
(active caspase-3+) cells in the P0, P1, 
P2, and P3 populations after incubation 
with E7-specific CTLs at a 1:1 ratio for 4 
hours (isotype control staining is indicated 
by solid gray region; anti-active caspase-3 
staining is indicated by black lines). (A and 
C) Numbers below blots indicate expres-
sion as measured by fold change. Error 
bars represent mean ± SD. Original mag-
nification, ×40.
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We assessed the status of a panel of important signaling cascades 
— including those controlled by Akt, Erk, and p38 — in P0 cells com-
pared with that in P3 cells. Among these, we found the phosphory-
lation of Akt to be 3-times higher in P3 cells than in P0 cells (Figure 
3A). We then asked whether phosphorylation of Akt in P3 cells is 
mediated through Nanog. Interestingly, delivery of siNanog into P3 
cells reduced Akt phosphorylation by over 2 fold. Conversely, intro-
duction of Nanog into P0 cells increased Akt phosphorylation by 
over 4 fold (Figure 3, B and C). To explore the relationship between 
the Nanog-induced stem-like phenotype and the Akt pathway, we 
treated Nanog-transduced P0 cells with API2, an inhibitor of Akt 
phosphorylation, or DMSO control (Figure 3D). API2-treated 
Nanog+ cells formed 3-times fewer spheres and contained almost 
3-times more apoptotic cells compared with DMSO-treated Nanog+ 
cells (Figure 3, E and F). To exclude potential off-target effects of 
API2, we performed the same experiment using siRNA-targeting Akt 
(siAkt) to block the Akt pathway and observed similar results (Figure 
3, G–I). Thus, our data indicate that Nanog mediates the pro-survival 
and stem-like phenotype of tumor cells through the Akt pathway.
Because Nanog regulates multiple gene expression programs 
critical for self-renewal of stem cells, we asked whether Nanog 
mediates its effects through its transcriptional function. To 
address this, we engineered a mutant form of Nanog (Nanog MT) 
cDNA in which the CD2 domain — known to be pivotal for its 
transcriptional function (15, 16) — contains 3 inactivating point 
mutations (E264G, E268G, and E272A) (ref. 16 and Supplemen-
tal Figure 4A). P0 cells transfected with Nanog MT, relative to 
those transfected with wild-type Nanog (Nanog WT), had reduced 
expression of a luciferase reporter gene introduced under the con-
trol of Nanog-binding elements in the pGL3-5×NBE construct 
(Supplemental Figure 4B).
P0 cells transfected with Nanog MT, in contrast with those trans-
fected wit Nanog WT, failed to markedly increase phosphorylation 
of Akt or change expression levels of cyclin A or p21 (Figure 4, A and 
B). Moreover, while addition of Nanog WT accelerated the growth 
and improved the sphere-forming capacity of P0 cells, addition of 
Nanog MT had no substantial impact on these parameters (Figure 
4, C and D). Also, delivery of Nanog WT to P0 cells reduced lysis by 
CTLs by over 80%, while delivery of Nanog MT did not significantly 
alter the susceptibility of P0 cells to lysis (Figure 4E).
We reasoned that the enhanced growth, survival, and immune 
resistance conferred by Nanog may be due to its effects on proteins 
involved in the apoptotic pathway. We thus measured the expres-
sion levels of a panel of proapoptotic or antiapoptotic proteins. 
Notably, the amount of the antiapoptotic molecule Mcl-1 was ele-
vated 3 fold in Nanog WT–transfected cells and slightly in Nanog 
Figure 3
Nanog promotes the stem-like and immune-resistant phenotype of tumor cells through the Akt pathway. (A–C) Western blot analysis of expression 
and activation status (A) of a panel of major signaling molecules in P0 or P3 cells or (B) of Nanog and pAkt expression in P3 cells treated with 
siGFP or siNanog or (C) in empty vector– or Nanog cDNA–transfected P0 cells. β-Actin was included as an internal loading control. (D and G) 
Western blot analysis of pAkt or total Akt levels in Nanog-transfected P0 cells treated with either (D) API2 and DMSO control or (G) siAKT and 
siGFP control. (E and H) Sphere-forming capacity of Nanog-transfected P0 cells treated with either (E) API2 and DMSO control or (H) siAKT 
and siGFP control. Original magnification, ×40. (F and I) Flow cytometry analysis of the frequency of apoptotic (active caspase-3+) cells in 
Nanog-transfected P0 cells treated with either (F) API2 and DMSO control or (I) siAKT and siGFP control after incubation with E7-specific CTLs 
at a 1:1 ratio for 4 hours (isotype control staining is indicated by solid gray region; anti-active caspase-3 staining is indicated by black lines). (A–D 
and G) Numbers below blots indicate expression as measured by fold change. Error bars represent mean ± SD.
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MT–transfected cells (Figure 4F). Knockdown of Mcl-1 using 
siRNA restored the sensitivity of Nanog-transduced tumor cells 
to lysis by CTLs, confirming that Mcl-1 is important for Nanog-
mediated immune escape (Figure 4G). Furthermore, inhibition of 
the Akt pathway with API2 or siRNA diminished Mcl-1 expres-
sion by 3 or 10 fold, respectively (Figure 4, H and I), establishing 
a direct link between this pathway and Mcl-1. Thus, our findings 
demonstrate that Nanog promotes a death-resistant and stem-like 
phenotype in tumor cells by initiating a transcriptional program 
that ultimately leads to Akt-dependent upregulation of Mcl-1.
Figure 4
The transcriptional function of Nanog is required for it to induce a stem-like phenotype and activate an antiapoptotic program in human cancer cells. 
(A and B) Western blot analysis of (A) Nanog, pAkt, or Akt as well as (B) cyclin A or p21 expression in P0 cells transfected with either Nanog WT or 
Nanog MT cDNA. (C) Growth rate of Nanog WT– transfected cells versus that of Nanog MT–transfected cells in culture. (D) Sphere-forming capacity 
of Nanog WT–transfected P0 cells versus that of Nanog MT–transfected P0 cells in low-density suspension culture. Original magnification, ×40. (E) 
Flow cytometry analysis of the frequency of apoptotic (active caspase-3+) cells in Nanog WT– or Nanog MT–transfected P0 cells after incubation with 
E7-specific CTLs. (F) Western blot analysis of expression of a panel of proapoptotic or antiapoptotic proteins in Nanog WT– or Nanog MT–transfected 
P0 cells. (G) Western blot analysis of Mcl-1 expression in Nanog-transfected P0 cells treated with siGFP or siRNA-targeting Mcl-1 (siMcl-1). Flow 
cytometry analysis of the frequency of apoptotic (active caspase-3+) cells in Nanog-transfected P0 cells treated with siGFP or siMcl-1 after incubation 
with E7-specific CTLs. (H and I) Western blot analysis of Nanog-transfected P0 cells, characterizing expression of pAkt, Akt, p21, and Mcl-1 after 
delivery of either (H) API2 and DMSO control or (I) Akt-specific siRNA and siGFP control. β-Actin was included as an internal loading control (A, B, 
and F–I). (A, B, and F–I) Numbers below blots indicate expression as measured by fold change. Error bars represent mean ± SD.
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Nanog triggers Akt signaling in tumor cells through transcriptional activa-
tion of Tcl1a. We next aimed to elucidate the process by which Nanog 
triggers the Akt pathway. The signaling molecules Eras and Pten 
are both known to be involved in activation of the Akt pathway 
(17, 18). Thus, we measured the levels of these proteins in P0 cells 
with and without Nanog transduction. There was no detectable 
change in either Eras or Pten expression after Nanog transduction 
(data not shown). Besides these proteins, Tcl1a has been reported 
as an adaptor that facilitates Akt dimerization and cross-phospho-
rylation, thereby initiating the Akt pathway. We therefore assessed 
Tcl1a expression after introduction of Nanog. Notably, the fre-
quency of Tcl1a+ cells increased over 4 fold after delivery of Nanog 
into P0 cells (Figure 5A). To verify that Tcl1a controls activation of 
the Akt pathway as well as tumor phenotype in our system, we used 
siRNA to knockdown Tcl1a (siTCL1a) in Nanog+ cells and measured 
key biochemical and functional features of the tumor cells. siT-
CL1a-treated Nanog+ tumor cells had over 2-fold reduction in Akt 
phosphorylation (Figure 5B). In addition, these cells had 2.6-times 
more p21, 10-times less cyclin A, 
and over 3-times less Mcl-1 com-
pared with siGFP-treated Nanog+ 
tumor cells (Figure 5C). Delivery 
of siTCL1a also retarded prolifer-
ation, diminished sphere-forming 
capacity, and increased suscepti-
bility to lysis by CTLs compared 
with delivery of siGFP (Figure 5, D 
and E). We also characterized the 
effect of silencing Tcl1a as well as 
Akt in P3 tumor cells using siRNA 
and observed similar results (Sup-
plemental Figure 6). In addition, 
we noted that inhibition of Tcl1a 
or Akt reduced tumor growth in 
mice and rendered the tumor 
sensitive to lysis by CTLs (Sup-
plemental Figures 6 and 7). These 
results suggest that Tcl1a acts 
downstream of Nanog in initiat-
ing the Akt pathway and stimu-
lating tumor growth and survival.
This prompted us to further 
explore the connection between 
Nanog and Tcl1a. We performed 
qRT-PCR and found that P3 cells 
have 4-times more Tcl1a mRNA 
than P0 cells (Figure 6A). Also, 
Nanog-transduced P0 cells have 
2.4-times more Tcl1a mRNA 
than empty vector–transduced 
P0 cells (Figure 6B). Intro-
duction of Nanog MT cDNA, 
however, only led to a marginal 
increase in Tcl1a expression 
(Supplemental Figure 4C). These 
data show that Nanog induces 
upregulation of Tcl1a. We were 
further encouraged by the pres-
ence of Nanog-binding elements 
in the Tcl1a promoter region, 
suggesting the possibility that Nanog is a direct transcriptional 
activator of Tcl1a. We engineered reporter constructs containing 
the luciferase gene under the control of either a wild-type Tcl1a 
promoter (WT-Tcl1a-pGL3) or a Tcl1a promoter in which the 
Nanog-binding elements have been mutated (Mut-Tcl1a-pGL3) 
(Figure 6C). Expression of luciferase from WT-Tcl1a-pGL3 was 
over 3-times stronger in P3 cells compared with that in P0 cells, 
consistent with the abundance of Nanog+ cells in the P3 line (Fig-
ure 6C). Importantly, among the P3 cells, expression of luciferase 
was more robust from WT-Tcl1a-pGL3 than from Mut-Tcl1a-
pGL3 (Figure 6C). We next performed a ChIP assay using an anti-
Nanog antibody to demonstrate that Nanog associates with the 
Tcl1a promoter region. We successfully recovered DNA flanking 
the Nanog-binding elements in the Tcl1a promoter in the P3 cells 
and, to a lesser extent, in the P0 cells, proving that Nanog directly 
interacts with promoter elements upstream of the Tcl1a gene. 
Altogether, these findings establish that Nanog triggers the Akt 
pathway through transcriptional activation of Tcl1a.
Figure 5
Nanog triggers the Akt pathway through upregulation of the Akt activator protein Tcl1a. (A) Flow cytom-
etry analysis of the frequency of Tcl1a+ cells among Nanog-transfected P0 cells treated with siGFP or 
siTCL1A. (B) Western blot analysis of pAkt, p21, cyclin A, and Mcl-1 expression in Nanog-transfected P0 
cells treated with siGFP or siTCL1A. β-Actin was included as an internal loading control. Numbers below 
blots indicate expression as measured by fold change. (C) Growth rate in culture of Nanog-transfected P0 
cells treated with siGFP versus siTCL1A. Cells were harvested at the indicated times and counted after 
trypan blue staining to exclude dead cells. (D) Sphere-forming capacity of Nanog-transfected P0 cells 
treated with siGFP or siTCL1A in low-density suspension culture. Original magnification, ×40. (E) Flow 
cytometry analysis of the frequency of apoptotic (active caspase-3+) cells in Nanog-transfected P0 cells 
treated with siGFP or siTCL1A after incubation with E7-specific CTLs at a 1:1 ratio for 4 hours (isotype 
control staining is indicated by solid gray region; anti-active caspase-3 staining is indicated by black lines). 
Error bars represent mean ± SD.
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Nanog expression in tumor cells correlates with stage and prognosis of 
cervical cancer. Having unraveled the molecular mechanism by 
which Nanog promotes tumor growth, we aimed to determine the 
clinical relevance of Nanog expression in human cancer. We com-
pared Nanog expression levels by immunohistochemistry (IHC) 
in cervical tissue biopsies from patients with cervical intraepithe-
lial neoplasia (CIN) or invasive cervical carcinoma. There was an 
increasing amount of Nanog expression as tumor stage progressed 
from low-grade CIN to high-grade CIN to cancer (Figure 7, A and 
B). A parallel trend between expression level and disease stage 
was noted for Tcl1a and phosphorylated Akt (pAkt), reinforcing 
the link between Nanog and the Tcl1a/Akt axis (Figure 7, A and 
B, and Table 1). Furthermore, patients diagnosed with cervical 
cancer had greater Nanog, Tcl1a, and pAkt levels in tumor tissue 
than in nonadjacent normal tissue (Figure 7B). We next examined 
the relationship of Nanog expression with patients’ outcomes. 
Kaplan-Meier plots demonstrated that patients with high Nanog 
expression displayed substantially worse disease-free (mean of 46.3 
versus 54.6 months, P = 0.008) and overall (mean of 53.6 versus 
57.9 months, P = 0.015) survival compared with that of patients 
with low Nanog expression (Figure 7C). These results suggest that 
Nanog expression may be involved in cervical cancer development 
and have prognostic value in patients.
We next examined the correlation in CIN or carcinoma in situ 
(CIS) specimens among expression of Nanog and Tcl1a and 
pAkt, factors we found to be critical for Nanog function. Nota-
bly, expression of Nanog was positively associated with expres-
sion of both Tcl1a (P = 0.045) and pAkt (P = 0.030), confirming 
that Nanog acts through the Tcl1a/Akt axis in humans (Table 
2). Notably, expression of Sox2 — another protein important for 
self-renewal of stem cells — was not associated with expression of 
Tcl1a or pAkt (Supplemental Table 1). Altogether, our data indi-
cate that Nanog expression serves as an important prognostic 
factor in human cervical neoplasia.
The Nanog/Tcl1a/Akt axis is conserved across multiple cancer types. We 
next profiled Nanog expression across a variety of human cancer 
cell lines besides cervical cancer. We found Nanog at high levels 
in breast, lung, liver, ovarian, and colon cancer cell lines (Figure 
8A). Notably, Nanog was present in 4 out of 4 colon cancer lines 
that we screened (Figure 8A). To verify the phenotypic effects of 
Nanog in these different types of cancer, we selected 3 represen-
tative lines, CUMC6, H1299, and HCT116 (from cervical, lung, 
and colon cancer, respectively), and performed biochemical and 
functional assays. Knockdown of Nanog with siRNA consistently 
and robustly dampened expression of Tcl1a, pAkt, cyclin A, and 
Mcl-1 across all tested lines (Figure 8B). Furthermore, siNano-
g-treated tumor cells also had diminished sphere-forming capacity 
and were more susceptible to immune-mediated lysis, compared 
with siGFP-treated tumor cells (Figure 8, C and D). These results 
demonstrate that overexpression of Nanog is a common feature of 
human cancer and that the biochemical and functional properties 
of the Nanog/Tcl1a/Akt signaling axis are conserved across mul-
tiple types of cancer.
Inhibition of Nanog leads to immune-mediated tumor regression in a 
preclinical cancer model. Because — based on our screen of a panel 
of human cancer lines — Nanog expression appears to be a com-
mon feature of human cancer that confers immune resistance, we 
reasoned that inhibition of Nanog may serve as an interventional 
strategy for immune-based cancer therapy. We chose to evalu-
ate this idea in the setting of a human colon carcinoma model, 
Figure 6
Nanog is a transcriptional activator of Tcl1a. (A 
and B) Quantitative RT-PCR analysis of Tcl1a 
mRNA expression (A) in P0 or P3 cells or (B) 
in P0 cells transfected with empty vector or 
Nanog cDNA. β-Actin was included as an inter-
nal loading control. (C) Diagram of plasmids 
encoding wild-type (WT) or mutant (Mut) 
Tcl1a promoter (nt –1,286 to +1) cloned into 
pGL3 vector containing the luciferase gene. 
In the mutant plasmid, the adenine residues 
in the Nanog-binding site (nt –796 to –791) 
have been replaced with cytosine residues to 
diminish Nanog binding (left). Luciferase enzy-
matic assay in P0 or P3 cells transfected with 
the indicated plasmids (right). Error bars rep-
resent mean ± SD. (D) Strategy for ChIP assay, 
in which a fragment corresponding to nt –938 
to –721, which contains the Nanog-binding 
region, of the Tcl1a promoter is amplified by 
PCR (left). Representative gel of ChIP assay 
in P0 and P3 cells. Input was included as posi-
tive control, and IgG was included as negative 
control (right). Numbers below blots indicate 
expression as measured by fold change.
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HCT116. Because HCT116 cells have not been reported to express 
any definitive, readily targetable tumor-associated antigens, we 
introduced a single-chain trimer (SCT) composed of the heavy 
chain of mouse MHC class I (H2-Db), β2-microglobulin, and the 
H2-Db–restricted E7 epitope (aa 49–57) into these cells (Supple-
mental Figure 5A). The E7 epitope is presented on the plasma 
membrane by the chimeric H2-Db, enabling the tumor cells to be 
recognized and killed by E7-specific CTLs (Supplemental Figure 
5, B–D). Thus, use of the SCT technology allows us to effectively 
model immune-based therapy in the context of a prevalent tumor 
type characterized by high Nanog expression.
To test the therapeutic value of Nanog inhibition, we inoc-
ulated HCT116/SCT-E7 cells into NOD/SCID mice and 10 
days later intravenously administered chitosan nanoparticles 
carrying Nanog- or GFP-targeting siRNA. Chitosan nanoparti-
cles have been previously demonstrated to be highly efficient 
in delivering siRNA into the tumor mass via the enhanced per-
meability and retention effect (19–21). Sixteen days after tumor 
challenge, mice received adoptive transfer of E7-specific CTLs 
(Figure 9A). Delivery of siNanog elicited a profound thera-
peutic effect, and, when combined with adoptive transfer, the 
tumor was virtually undetectable, even 50 days after tumor 
challenge (Figure 9, B and D). Importantly, 100% of mice that 
received both siNanog and adoptive transfer survived, even 80 
days after tumor challenge; by contrast, all the animals in the 
other groups had died by then (Figure 9C). Consistent with 
our in vitro results, we observed reduced levels of pAkt, Tcl1a, 
Mcl-1, and cyclin A, as well as elevated levels of p21, in tumor 
tissue from siNanog-treated mice compared with that from siG-
FP-treated mice (Figure 9E). Additionally, the siNanog-treated 
tumor contained fewer proliferating cells than the siGFP-treated 
tumor, as measured by Ki67 staining, and this was unaffected by 
adoptive transfer (Figure 9F). We assessed antigen-specific CTL 
infiltration into the tumor by labeling the T cells with CFSE 
prior to adoptive transfer and then counting the frequency of 
CFSE+ cells inside the tumor following transfer. We observed a 
slight, but not statistically significant, increase in the frequency 
of antigen-specific CTLs in the tumors of siNanog-treated mice 
compared with that in siGFP-treated mice (Figure 9G). However, 
the overall cytotoxic effect of these CTLs was greater after deliv-
ery of siNanog relative to that after delivery of siGFP, as indi-
cated by the percentage of apoptotic tumor cells (Figure 9H). 
Interestingly, there was no difference in the percentage of apop-
totic tumor cells in mice administered siGFP with or without 
adoptive transfer, suggesting that the HCT116 cells were resis-
tant to immune-mediated control due to the presence of Nanog 
(Figure 9H). Taken together, our data show that inhibition of 
Nanog represents an attractive, widely applicable strategy for 
the control of human cancer, either as a sole modality or, syner-
gistically, as part of an immune-based therapy.
Discussion
It is now generally accepted that CSCs play a prominent role in 
the maintenance and progression of certain cancers (9). CSCs 
are commonly spared and thus enriched by conventional forms 
of cancer therapy, such as radiation or pharmacologic agents 
(22–25). However, the relationship between CSCs and the host 
immune system is largely unknown. We previously demonstrated 
in a mouse model that vaccination drives the evolution of tumor 
cells toward a phenotype resembling CSCs in a process requiring 
Nanog, a transcription factor pivotal in self-renewal of embry-
onic stem cells (14). It was unclear at the time whether the emer-
gence of stem-like Nanog+ tumor cells was a general consequence 
of immune selection or merely an artifact of the particular vac-
cination system we used. To address this issue, here we used in 
vitro immune selection, in which the cells are directly pulsed with 
antigen and then exposed in sequential rounds to antigen-spe-
cific CTLs, to generate human cancer cells. The result of such a 
selection process was, after 3 rounds, a line of tumor cells, P3, 
that were almost completely impervious to lysis by CTLs. This P3 
line thus enabled us to study the molecular signatures that facil-
itate development of immune escape. The P3 line had a stem-like 
and highly tumorigenic phenotype. Strikingly, we also found that 
nearly 100% of the P3 cells had abundant Nanog expression and 
that the stem-like phenotype of these cells was critically depen-
dent on Nanog. Since we have demonstrated this with 2 distinct 
selection methods, we infer that Nanog+ tumor cells may also be 
enriched by naturally occurring adaptive immune surveillance. 
Nonetheless, all of our experiments thus far have been conducted 
with externally imposed selection techniques, so it is plausible 
that this model might not apply to physiological host-tumor 
interactions in the absence of any interventions that modulate the 
status of the immune system. Nonetheless, the evidence we have 
is sufficient to conclude that enhancement of a stem-like tumor 
phenotype through Nanog is a general outcome of imposed 
immune selection, regardless of the mechanism by which such 
selection is brought forth (Figure 10A).
It is important to note that Nanog+ tumor cells in P3 cells are 
not equivalent to conventional CSCs. Indeed, while virtually all 
P3 cells had Nanog expression, only a small fraction of these cells 
stained positive for various stemness markers. There is currently 
no broad consensus about the precise molecular definition of 
CSCs, hampering our ability to accurately quantify the number 
of CSCs in the P3 line compared with its parent line, P0. However, 
based on the widely accepted hallmarks of CSCs — namely, sphere-
forming capacity, tumorigenicity, and expression of stemness 
markers — we consistently observed that the P3 population exhib-
ited more of a stem-like phenotype relative to the P0 population. 
It is reasonable to posit a model in which Nanog, in conjunction 
with other factors (which may or may not be present within indi-
vidual cells), promotes the conversion of tumor cells into CSCs, 
as has been proposed (8, 26–28). As we and others have shown (14, 
29, 30), besides its ability to turn tumor cells into CSCs, Nanog 
also confers a growth and survival benefit. Therefore, immune 
selection favors Nanog+ cells, and a fraction of these cells contain 
the accessory factors necessary to be fully reprogrammed into 
bona fide CSCs. The detailed molecular events involved in the 
conversion of tumor cells into CSCs are still shrouded in mystery. 
Our focus in this study was to shed light on the pathway by which 
Nanog acts to bring about the stem-like and immune-resistant 
phenotype of tumor cells.
In this vein, we uncovered the Tcl1a/Akt signaling axis as the 
downstream component triggered by the transcriptional function 
of Nanog. Notably, after depletion of Tcl1a or Akt, the stem-like 
and immune-resistant phenotype of P3 cells or Nanog-transduced 
P0 cells was almost entirely lost, indicating that the Akt pathway 
is the primary route through which Nanog acts to promote this 
phenotype. Moreover, we did not detect any influence of Nanog 
on expression or activation of p38 or Erk, although we cannot 
exclude possible contributions from other signaling cascades. Our 
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discovery of the pathway through which Nanog acts is significant 
because it links a master regulator of stem cells to a major signal-
ing axis often exploited by tumor cells. This connection immedi-
ately hints at several potentially promising therapeutic targets to 
control cancer in the clinic (Figure 10B).
Indeed, we found that Nanog expression was elevated in multiple 
types of human cancer and depletion of Nanog reduced the stem-
like character of tumor cells and rendered them more vulnerable to 
lysis by CTLs. Furthermore, Nanog expression in tumor tissue cor-
related with stage and outcome of disease in patients with cervical 
neoplasia. These data underscore the value of Nanog expression 
as a prognostic factor in cervical neoplasia and strongly suggest 
that the functions of Nanog on tumor cells that we observed in 
vitro hold true in patients with cancer as well. Importantly, Nanog 
expression in precancerous cervical tissue was correlated with both 
Tcl1a and pAkt expression, validating the biochemical pathway 
we proposed. It is also notable that Nanog expression correlated 
with resistance of cervical tumors to chemotherapy, such as the 
platinum-based agent cisplatin (Supplemental Table 2). Previous 
reports further found Akt activation to be associated with cisplatin 
resistance in various types of tumor, including those of the uterine 
cervix (31–34). Therefore, it will be important in future studies 
to assess involvement of the Nanog/Tcl1a/Akt axis in promoting 
tumor resistance to chemotherapy.
Individuals with productive HPV infection frequently mount a 
robust immune response against the E6 and E7 HPV antigens. In 
fact, 90% of individuals who test positive for HPV will clear the 
virus within 6 to 24 months. Moreover, spontaneous regression 
occurs in 60% to 80% of people with HPV-associated, low-grade 
CIN, and only 1% eventually advance to cervical CIS. Escape of 
the tumor from immune control is believed to be an essential step 
in the development of cervical cancer (35). As evidence of this, 
patients with high frequencies of tumor-infiltrating CTLs typi-
cally have no detectable lymph node metastasis and have a good 
prognosis (36, 37). Furthermore, patients with late-stage cervical 
cancer usually possess a high amount of regulatory T cells and 
a low amount of natural killer cells (38). Our data suggest that, 
in addition to immune escape, acquisition of intrinsic immune 
resistance by tumor cells through the Nanog/Tcl1a/Akt pathway 
may also be important in the progression of cervical neoplasia. We 
found the degree of Nanog expression to be positively correlated 
with disease stage and outcome in patients with cervical neoplasia. 
Taken together, our results provide insight into the events that 
occur at the level of tumor cells in the onset and development of 
cervical cancer.
Due to the stem-like and immune-resistant phenotype medi-
ated by Nanog across multiple types of human cancer, this pro-
tein represents a prime target for therapeutic intervention. We 
provided proof of this concept by knocking down Nanog in a 
xenograft mouse model of human colon cancer. Notably, in this 
setting, Nanog inhibition alone strongly retarded tumor growth 
and, when combined with adoptive transfer of tumor-specific 
CTLs, virtually cured animals of disease. As we understand more 
and more about CSCs and their sinister role in tumor progression, 
metastasis, and relapse, it is increasingly clear that cancer therapy 
should also be directed against this rare but robust population of 
cells in order to provide meaningful, long-term benefit to patients. 
As we have demonstrated here, Nanog inhibition appears to be 
an ideal strategy for achieving this, particularly in the context of 
immune-based therapy.
Methods
Mice. 6- to 8-week-old female NOD/SCID mice (Central Lab Animal 
Inc.) were maintained and handled under a protocol approved by the 
Korea University Institutional Animal Care and Use Committee (KUIA-
CUC-2009-126). All procedures were performed in accordance with recom-
mendations for the proper animal care and use.
DNA constructs. To generate pMSCV/Nanog, cDNA encoding human 
Nanog was amplified from pSIN-EF2-Nanog-Pur (Addgene) using 
primer set 5′-GCCTCGAGATGAGTGTGGATCCAGCTTG-3′ (forward) 
and 5′-GCGAATTCTCACACGTCTTGAGGTTG-3′ (reverse). The ampli-
fied cDNA was cloned into XhoI/EcoRI restriction sites of the pMSCV ret-
roviral vector (Clontech). The promoter region of the Tcl1a gene was iso-
lated by PCR from genomic DNA extracted from CaSki/Db P3 cells using 
primer set 5′-GGGGTACCTCTGTGGCTATCTAGGTCT-3′ (forward) 
and 5′-AATAAGCTTCTTGGGGCGGGACCCCGGGT-3′ (reverse). The 
PCR products were digested with KpnI and HindIII and subcloned into 
the KpnI/HindIII restriction sites of the pGL3-Basic vector (Promega). 
To generate pMSCV/SCT-E7, a DNA fragment encoding the H2-Db–
restricted E7 epitope (aa 49–57) and flanked by AgeI and NheI restric-
tion sites was synthesized by annealing 2 single-stranded DNA oligo-
nucleotides: 5′-CCGGAGAGCCCATTACAATATTGTAACCTTT-3′ and 
5′-CTAGTCTCGGGTAATGTTATAACATTGGAAA-3′. This fragment 
was then subcloned into the AgeI/NheI restriction sites of the pIRES-E6-
2m-Kb plasmid reported previously (39) to swap the E6 antigen with E7 
and produce pIRES-E7-2m-Kb. H2-Db heavy chain DNA was amplified 
by PCR using TC-1 cDNA templated and cloned into pIRES-E7-2m-Kb 
to replace H2-Kb with H2-Db. Finally, E7-2m-Db was amplified with PCR, 
using pIRES-E7-Db as the template, and subsequently cloned into the 
BglII/XhoI sites of pMSCV (Clontech). In all cases, plasmid integrity was 
confirmed by DNA sequencing.
Site-directed mutagenesis. The QuikChange XL Site-Directed Mutagen-
esis Kit was used (Stratagene) according to the manufacturer’s instruc-
tions. To create mutations in the Nanog gene, the following primers were 
used: E264G, 5′-TGCCAGTGACTTGGGGGCTGCGTGGAAG-3′ (for-
ward) and 5′-CTTCCAAGGCAGCCCCCAAGTCACTGGCA-3′ (reverse); 
E268G, 5′-GAGGCTGCCTTGGGAGCTGCTGGGGAA-3′ (forward) 
and 5′-TTCCCCAGCAGCTCCCAAGGCAGCGC-3′ (reverse); E272A, 
5′-GGAAGCTGCTGGGGCAGGCCTTAATGTAA-3′ (forward) and 
5′-TTACATTAAGGCCTGCCCCAGCAGCTTCC-3′ (reverse). To create 
Figure 7
Nanog expression in human cervical neoplasia specimens correlates 
with stage and outcome of disease. (A) Representative image of 
immunohistochemical staining of Nanog, Tcl1a, and pAkt expression 
in cervical tissue from patients with low-grade CIN, high-grade CIN, 
and cervical carcinoma. Boxed regions are displayed at high magnifi-
cation in insets (scale bar: 200 μm). (B) Box plot depiction of IHC data. 
The IHC score is an index of Nanog, Tcl1a, or pAkt expression and 
was computed based on intensity and tissue area of positive staining. 
In box-and-whisker plots, horizontal bars indicate the medians, boxes 
indicate 25th to 75th percentiles, and whiskers indicate the lowest and 
highest datum within 1.5 interquartile range of the lower and upper 
quartiles, respectively. Symbols indicate individual samples. Numbers 
associated with symbols indicate case numbers. (C) Kaplan-Meier 
plots for patients with cervical cancer stratified according to FIGO 
stage, lymph node metastasis, or Nanog, Tcl1a, or pAkt expression. 
For patients with high Nanog expression, mean disease-free and over-
all survival were 46.3 months and 53.6 months (n = 94), respectively. 
For patients with low Nanog expression, mean disease-free and overall 
survival were 54.6 months and 57.9 months (n = 76), respectively. 
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conical tube supplemented with 10% FBS and penicillin/streptomycin (50 
U/ml). Surviving CaSki-Db cells were further cultured in the presence of 
puromycin (10 mg/ml) to deplete CTLs. Expanded cells were termed P1 
cells. The above procedure was repeated twice to create the P3 line.
Tumor sphere-forming assay. CaSki-Db P0 or P3 cells were plated at 5 × 103 
cells per well in 6-well, super-low adherence vessels (Corning) containing 
serum-free DMEM-F12 (Thermo Scientific) supplemented with epidermal 
growth factor (20 ng/ml), basic fibroblast growth factor (20 ng/ml), and 
1XB27. Medium was replaced every 3 days to replenish nutrients. Colonies 
more than 2 mm in diameter were counted under a microscope.
Tumorigenicity assay. CaSki-Db P0 or P3 cells were harvested by trypsin 
treatment and then washed and resuspended in Opti-MEM. NOD/SCID 
mice were subcutaneously injected with 103 or 104 P0 or P3 cells. Tumor 
formation was monitored at least 3 times per week. After 18 days, tumor 
tissue was excised and weighed.
Real-time quantitative RT-PCR. Total RNA from CaSki-Db P0 or P3 cells 
was purified using TRIzol reagent (Invitrogen). First-strand synthesis and 
real-time PCR were performed and quantified by LightCycler 1.5 (Roche) 
to detect Tcl1a mRNA using TaqMan Universal SYBR Green Master Mix 
(Roche) with the following primer set: 5′-GCCTGGGAGAAGTTCGT-
GTA-3′ (forward) and 5′-TCAGTCATCTGGCAGCAGC-3′ (reverse).
Immunofluorescence microscopy. CaSki-Db P0, P1, P2, or P3 cells were fixed 
mutations in the Nanog-binding site of Tcl1a, the following primers 
were used: 5′-GCCTTAGTGGGCCTGCGTTACTGCAAAATAAAGT-
GAAATTGT-3′ (forward) and 5′-CAGTAACGCAGGCCCACTAAGG-
CAATTAAGAAAGTCATGCA-3′ (reverse). Thermal cycling conditions 
for PCR were 95°C for 1 minute; 18 cycles of 95°C for 50 seconds, 60°C 
for 50 seconds, and 68°C for 7 minutes; and 68°C for 7 minutes. PCR 
products were digested with DpnI at 37°C for 1 hour and transformed 
into XL10-Gold ultracompetent bacterial cells (Stratagene). Mutations 
were verified by DNA sequencing.
siRNA constructs. Synthetic siGFP, siNanog, and siTcl1a (Invitrogen) 
had the following sequences: GFP, 5′-GCAUCAAGGUGAACUUCAA-3′ 
(sense), 5′-UUGAAGUUCACCUUGAUGC-3′ (antisense); Nanog, 
5′-GCAACCAGACCUGGAACAAUU-3′ (sense), 5′-UUGUUCCAGGU-
CUGGUUGCUU-3′ (antisense); and Tcl1a, 5′-GCCCUUAACCAUCGA-
GAUA-3′ (sense), 5′-UAUCUCGAUGGUUAAGGGC-3′ (antisense). siAkt 
(no. 6211) was purchased commercially (Cell Signaling Technology). 
siRNA was delivered in vitro into 6-well plates at a dose of 300 pmol 
per well using Lipofectamine 2000 (Invitrogen). siRNA was delivered 
into mice after formulation with chitosan nanoparticles as described 
previously (20). Briefly, tripolyphosphate (0.25% w/v) and siRNA (1 
μg/μl) were combined in RGD-chitosan solution, and the mixture was 
incubated at 4°C for 40 minutes. siRNA-loaded nanoparticles were puri-
fied by centrifugation and injected into the tail veins of 
HCT116/SCT-E7 tumor-bearing mice.
Cells. CaSki, CUMC6, MCF7, MDA-MB-231, MDA-
MB-453, H1299, HepG2, OVCAR3, SKOV3, A2780, HT29, 
SNUC4, SW620, and HCT116 cells were obtained com-
mercially (ATCC). CaSki, CUMC6, MCF7, MDA-MB-231, 
MDA-MB-453, HepG2, SNUC4, SW620, and HCT116 
cells were cultured in Dulbecco’s Minimal Eagle Medium 
(DMEM). H1299, OVCAR3, SKOV3, and A2780 were cul-
tured in RPMI1640. All cells were cultured at 37°C in 5% 
CO2 atmosphere.
Generation of the CaSki-Db P3 tumor line. CaSki-Db P0 cells 
were produced by retroviral transduction of CaSki cells 
with pMSCV/H2-Db using pMSCV vector-Phoenix pack-
aging cell line system, followed by puromycin selection, as 
described previously (40). For immune selection, 106 CaSki-
Db cells were pulsed with 1 μg E7 peptide (aa 49–57, RAHY-
NIVTF) for 2 hours and mixed with 106 mouse E7-specific 
CTLs (1:1 ratio) for 4 hours in 10 ml DMEM in a 50-ml 
Table 1
Univariate and multivariate analyses of the association between prognostic variables and overall survival in cervical cancer
 Univariate analysis  Multivariate analysis 
 Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
FIGO stage (≥IIb) 3.39 (1.27–9.06) 0.015 1.52 (0.43–5.27) 0.507
Tumor grade (poor) 2.10 (0.81–5.46) 0.124  
Tumor size (>4 cm) 1.56 (0.59–4.10) 0.365  
LVI 2.20 (0.72–6.74) 0.166  
LN metastasis 4.14 (1.43–11.96) 0.009 4.11 (1.19–14.17) 0.025
Nanog+ 4.41 (1.26–15.40) 0.020 5.80 (1.26–26.51) 0.023
Tcl1a+ 1.67 (0.56–4.98) 0.358  
pAkt+ 5.10 (1.15–22.45) 0.031 4.21 (1.18–14.91) 0.026
Nanog+/Tcl1a+ 2.74 (0.92–8.16) 0.070  
Nanog+/pAkt+ 6.28 (1.72–22.85) 0.005 6.79 (1.85–24.92) 0.004
Nanog+/Tcl1a+/pAkt+ 3.04 (1.08–8.56) 0.056 4.37 (1.40–21.33) 0.012
LVI, lymphatic vessel invasion; LN metastasis, lymph node metastasis.
Table 2
Association between Nanog and Sox2, Tcl1a, or pAkt expression in CIN and CIS
   Nanog expression 
 Low % High % n P value
Sox2 expression     151 0.007
 Low 25 80.6 6 19.4 31 
 High 65 54.2 55 45.8 120 
Tcl1a expression     149 0.045
 Low 15 78.9 4 21.1 19 
 High 71 54.6 59 45.4 130 
pAkt expression     182 0.030
 Low 52 67.9 25 32.1 78 
 High 54 51.9 50 48.1 104 
Numbers in the “Low” and “High” columns refer to the number of samples meeting 
each condition. Numbers in the “n” column indicate the total number of samples 
tested for each condition.
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Cdk2, cyclin A, and cyclin E (Cell Signaling Technology); cIAP2, Mcl-1, 
Bcl-2, Oct4, Sox2, Klf4, and p21 (Santa Cruz Biotechnology Inc.); Nanog 
(Millipore); and β-actin (Sigma-Aldrich) were used at 1:1,000 dilution. 
Immune-reactive bands were visualized by enhanced chemiluminescence 
imaging (Elpis Biotech).
CTL assay. CaSki/Db P0, P1, P2 and P3 tumor cells were harvested by 
trypsinization, washed once with DMEM (Hyclone) containing 0.1% FBS, 
resuspended, and labeled in 1 ml 0.1% FBS containing DMEM and 10 
μM CFSE. The suspended cells were incubated for 10 minutes in a 37°C 
in 4% paraformaldehyde for 10 minutes. Cells were washed with PBS and 
treated with 0.2% Triton X-100 and blocked for 1 hour in 1% BSA solution. 
Cells were incubated overnight with primary antibodies against Nanog 
(Millipore) and then stained with Alexa Fluor 488–labeled goat anti-mouse 
IgG and DAPI. Expression of Nanog was analyzed by confocal laser scan-
ning microscopy (Carl Zeiss) as described previously (41).
Western blot. Lysate extracted from a total of 105 cells was used to per-
form Western blot as described previously (42). Primary antibodies against 
pAkt, Akt, pErk, Erk, Tcl1a, Eras, Pten, Bcl-xL, cIAP2, Bad, Bax, c-Myc, 
Figure 8
Nanog promotes a stem-like and immune-resistant phenotype in multiple types of human cancer. (A) Western blot analysis of Nanog expression 
in various human cancer lines. β-Actin was included as an internal loading control. (B) Western blot analysis of expression of Nanog, Tcl1a, pAkt, 
cyclin A, and Mcl-1 in human cancer cells treated with siGFP or siNanog. β-Actin was included as an internal loading control. (A and B) Numbers 
below blots indicate expression as measured by fold change. (C) Sphere-forming capacity of human cancer cells treated with siGFP or siNanog in 
low-density suspension culture (D) Flow cytometry analysis of the frequency of apoptotic (active caspase-3+) cells in human cancer cells treated 
with siGFP or siNanog after incubation with E7-specific CTLs at a 1:1 ratio for 4 hours (isotype control staining is indicated by solid gray region; 
anti-active caspase-3 staining is indicated by black lines). Original magnification, ×40. Error bars represent mean ± SD.
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applied for 30 minutes at 4°C. Antibodies used were CD133 (1:100; Abcam), 
CD166 (1:100; BD Pharmingen), CD44 (1:50; Cell Signaling Technology), 
and EpCAM (1:50; Abcam). Secondary antibodies (1:200) used were either 
goat anti-rabbit IgG or goat anti-mouse IgG labeled with Alexa 568 (Molec-
ular Probes), respectively. All data acquisition was performed on a FACSCal-
ibur flow cytometer (BD Biosciences) with CellQuest Pro software.
Luciferase enzymatic assay. CaSki-Db P0 and P3 cells were maintained in 
DMEM with 10% FBS and seeded at 105 cells per well in 12-well plates 1 
day prior to the assay. Cells were administered using Lipofectamine 2000 
(Invitrogen) with 500 ng WT- or Mut-Tcl1a-pGL3 reporter, together with 
50 ng CMV/β-galactosidase plasmid to normalize transfection efficiency. 
After 24 hours, cells were washed with PBS and permeabilized with Cell 
Culture Lysis Reagent (Promega). Luciferase activity was measured with a 
Turner Biosystems TD-20/20 luminometer after addition of 40 μl lucifer-
ase assay reagent (Promega). β-Galactosidase activity was measured with a 
uQuant microplate reader (BioTek) at 570-nm wavelength after addition of 
β-galactosidase assay reagent containing 1 mM chlorophenol red β-D-ga-
lactopyranoside substrate (Roche).
incubator with 5% CO2. After collection, the CFSE-labeled cells were resus-
pended in 10 μg/ml E7 peptide containing 1 ml DMEM. After 1 hour, 
CFSE-labeled CaSki/Db P0, P1, P2, and P3 cells were incubated for 4 hours 
with an E7-specific CD8+ T cell line at an E/T ratio of 1:1. After incubation 
for 4 hours at 37°C, the frequency of apoptotic cells was determined by 
staining with anti-active caspase-3 antibody and performing flow cytome-
try as described previously (43, 44).
Granzyme B apoptosis assays. Human granzyme B (Enzo Life Sciences) was 
introduced into cells with the BioPORTER QuikEase Protein Delivery Kit 
(Sigma-Aldrich). 5 × 104 cells per well were plated in 24-well plates and cul-
tured overnight at 37°C. Cells were washed, and 200 ng of granzyme B in 
Opti-MEM was added to each well. After incubation for 4 hours at 37°C, the 
frequency of apoptotic cells was determined by staining with anti-active cas-
pase-3 antibody and performing flow cytometry as described previously (14).
Flow cytometry analysis. CaSki/Db P0, P1, P2, and P3 tumor cells were har-
vested by trypsinization, washed, and resuspended in PBS. To detect CD133, 
CD166, CD44, and EpCAM expression, primary antibody incubation was 
applied for 1 hour at 4°C and rinsed, and then secondary antibody was 
Figure 9
Inhibition of Nanog renders the tumor vulnerable to immune-mediated control. (A) Diagram of the immune-based therapy regimen in mice 
implanted with HCT116 colon cancer cells transduced with plasmid encoding a SCT of H2-Db heavy chain linked to β2-microglobulin and the 
H2-Db–restricted E7 epitope (HCT116/SCT-E7). (B) Tumor growth and (C) survival of mice inoculated with HCT116/SCT-E7 and treated with the 
indicated reagents (5 mice/group). (D) Tumor mass of mice at 25 days after challenge. (E) Western blot analysis of Nanog, pAkt, Tcl1a, Mcl-1, 
cyclin A, and p21 expression in mice administered with siGFP or siNanog, with or without adoptive transfer of E7-specific CTLs. β-Actin was 
included as an internal loading control. Numbers below blots indicate expression as measured by fold change. (F) Flow cytometry analysis of the 
proliferation index of cells inside the tumor, as measured by the mean fluorescence intensity of Ki67 staining. (G) Flow cytometry analysis of the 
frequency of CFSE-labeled, E7-specific CTLs in the tumors of mice that received adoptive transfer, together with either siGFP or siNanog. (H) 
Flow cytometry analysis of the frequency of apoptotic (active caspase-3+) cells in the tumors of siGFP- or siNanog-treated mice, with or without 
adoptive transfer of E7-specific CTLs. Error bars represent mean ± SD.
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with cervical cancer received adjuvant platinum-based concurrent che-
moradiation therapy to reduce risk of relapse. This study was approved 
by the Institutional Review Boards of Gangnam Severance Hospital and 
the Office of Human Subjects Research at the NIH.
Tissue microarray construction and IHC. Tissue microarray (TMA) were 
produced from formalin-fixed, paraffin-embedded tumor and nonadja-
cent normal cervical tissue. Some of the paraffin blocks were provided 
by the Korea Gynecologic Cancer Bank through the Bio & Medical Tech-
nology Development Program of the Ministry of Education, Science and 
Technology. Areas representative of CIN, CIS, or cervical cancer were 
meticulously selected from H&E-stained slides. Tissue cylinders of 1.0-
mm diameter were extracted from selected areas of donor blocks and 
transplanted into recipient blocks using a tissue arrayer (Beecher Instru-
ments Inc.). H&E-stained TMA slides were examined at every 50th sec-
tion for the presence of tumor cells. For IHC, all paraffin sections were 
cut to 5-μm thickness, deparaffinized through xylene, and dehydrated 
with graded ethanol. Antigen retrieval for Nanog, Sox2, Tcl1a, and pAkt 
was performed in a pressure cooker containing prewarmed citrate buffer 
at pH 9.0 (Dako) for 10 minutes. Endogenous peroxidase activity was 
blocked by addition of 3% H2O2 for 10 minutes. Samples were incubated 
with primary antibodies against Nanog (1:100 dilution), Sox2 (1:500 
dilution) (Cell Signaling Technology), Tcl1a (1:1,000 dilution) (Milli-
pore), and pAkt (1:500 dilution) (Abcam) for 2 hours at 25°C. Samples 
stained for Nanog, Tcl1a, and pAkt were then incubated with EnVision 
Dual Link secondary antibody for 30 minutes, and samples stained for 
Sox2 were incubated with high-sensitivity EnVision FLEX linker and 
horseradish peroxidase antibody for 15 minutes (Dako). Samples were 
then developed by addition of 3,3-diaminobenzidine substrate for 10 
minutes and lightly counterstained with hematoxylin.
Digital image analysis. IHC-stained whole TMA sections were processed 
into digital format at ×20 magnification using an Aperio Scanscope CS 
(Aperio). The Scanscope acquired each image with a spatial resolution 
of 0.50 μm per pixel and an average file size of 220 MB. Each image was 
ChIP assay. The ChIP Kit (Millipore) was used according to the manu-
facturer’s instructions. Briefly, CaSki-Db P0 and P3 cells (107 per assay) 
were bathed in 1% formaldehyde at 25°C for 10 minutes for cross-link-
ing of proteins and DNA and then lysed in SDS buffer containing 1× 
protease inhibitor. DNA was sheared to 0.2- to 1-kb fragments by son-
ication using a Sonic Dismembrator Model 500 (Fisher Scientific). 
Immunoprecipitation was carried out by incubation with 2 μg anti-
Nanog antibody (Millipore) or mouse IgG (Upstate Biotechnology) as 
a negative control for 16 hours. To reverse the protein-DNA crosslinks, 
immunoprecipitated sample and input were incubated at 65°C for over-
night. After reversal of cross-linking, DNA fragments were purified on 
spin columns (Upstate Biotechnology). The region flanking the Nano-
g-binding site in the Tcl1a promoter was amplified by PCR from puri-
fied chromatin with the following primers: 5′-ATGTTCTTAGTGCCT-
GGTCAG-3′ (forward) and 5′-ATGATCAAAACCACCCCTCTGTA-3′ 
(reverse). The PCR product was resolved on a 2% agarose gel containing 
ethidium bromide and visualized under ultraviolet light.
Tumor treatment experiments. NOD/SCID mice were inoculated subcu-
taneously with 106 HCT116/SCT-E7 cells per animal and administered 
siNanog- or siGFP-loaded chitosan nanoparticles (5 μg/animal) via the 
tail vein at days 10, 12, and 14. Sixteen days after tumor challenge, mice 
received adoptive transfer with 107 E7-specific CTLs. This treatment proto-
col was repeated for 3 cycles at days 20, 30, and 40. Mice were monitored for 
tumor burden and survival for 50 and 80 days after challenge, respectively.
Human subjects. The study subjects consisted of 431 patients diagnosed 
with CIN (n = 193), CIS (n = 68), or cervical cancer (n = 170) after primary 
surgery at Gangnam Severance Hospital, Yonsei University College of 
Medicine, between 1996 and 2010. All patients were diagnosed histo-
logically, and disease was classified according to the International Fed-
eration of Gynecology and Obstetrics (FIGO) system. Medical records 
were reviewed to collect pertinent data, including age, disease stage, lym-
phovascular invasion, lymph node metastasis, platinum reagent resis-
tance, survival status, and tumor differentiation, type, and size. Patients 
Figure 10
Model depicting the role of Nanog in cancer progression and immune escape. (A) Enrichment of Nanog-expressing cells through sequential 
rounds of immune selection. (B) The molecular pathway through which Nanog promotes tumorigenicity and immune resistance of tumor cells.
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